Clinical trials show potent renoprotective effects of pitavastatin (PTV), although the precise mechanism for these renoprotective effects is not fully clarified. The aim of this study was to examine the antihypertensive and renoprotective effects of PTV, focusing on the nitric oxide (NO) system.
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, known as "statins, " are potent inhibitors of cholesterol synthesis. 1 Clinical trials and metaanalyses have demonstrated the renoprotective and antihypertensive effects of statins, 1,2 which have been recommended for use in chronic kidney disease to maintain renal function. 3 Clinical trials have reported that atorvastatin (ATV) and pitavastatin (PTV), which belong to the class of potent statins, are more effective in renoprotection. 4, 5 In chronic kidney disease patients, Bianchi et al. reported that ATV attenuated the reduction of creatinine clearance 6 ; however, Kimura et al. reported that ATV did not affect the reduction of estimated glomerular filtration rate. 7 In contrast, PTV treatment increased estimated glomerular filtration rate, suggesting a more potent renoprotective effect. 1, 8 However, a precise mechanism for the renoprotective effects of PTV remains unclear.
Several studies have demonstrated the beneficial effects of statins on blood pressure and renal function in animal models. Lovastatin reduced albuminuria and glomerulosclerosis in spontaneously hypertensive rats (SHR) 9 and in rats with 5/6 nephrectomy. 10 ATV reduced blood pressure in SHR by upregulation of nitric oxide synthase (NOS) expression and inhibition of Rho-kinase activity. 11 In Dahl salt-sensitive rats, pravastatin, ATV, and PTV provided renoprotective and depressor effects, with concomitant inhibition of oxidative stress. [12] [13] [14] Thus, statins exert their effects through various mechanisms.
Nitric oxide (NO) is a vasodilatory factor that plays a key role in blood pressure control. NO also has several renoprotective effects, including regulation of renal hemodynamics, as well as inhibition of tubular Na + reabsorption, tubuloglomerular Pitavastatin Upregulates Nitric Oxide Synthases in the Kidney of Spontaneously Hypertensive Rats and Wistar-Kyoto Rats feedback, and sympathetic nerve activity. 15 Renal dysfunction leads to impairment of endothelial function, thereby inducing NO dysfunction. 16 NO is synthesized by 3 isoforms of NOS: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). Along with protein expression and the abundance of its components, NO production is substantially adjusted by eNOS activity, which is regulated by several factors, including phosphorylation status. eNOS phosphorylation at serine 1177 (Ser1177) enhances its activity, whereas phosphorylation at threonine 495 (Thr495) inhibits its activity. 17 Several studies have indicated that the beneficial effects of statins are mediated in part by improvement of the NO system. 18, 19 We previously reported that ATV increased eNOS and nNOS expression, while inhibiting Rho-kinase activity, in the kidney of SHR. 11 PTV has been shown to upregulate eNOS mRNA expression in the kidney of 5/6 nephrectomized Wistar rats fed a high-cholesterol diet. 20 ATV and PTV increased eNOS expression in human umbilical vein endothelial cells, 21, 22 and PTV stimulated eNOS phosphorylation at Ser1177. 21, 22 Lin et al. reported that PTV and ATV increased eNOS expression in circulating endothelial progenitor cells collected from patients with hyperlipidemia and type 2 diabetes mellitus; however, only PTV stimulated eNOS phosphorylation at Ser1177. 21 These results imply that effects of PTV on the renal NOS system may differ from those of ATV.
In light of these findings, we hypothesized that PTV may exert antihypertensive and renoprotective effects in a different manner than those of ATV. Therefore, the aim of the present study was to examine the effects of PTV on blood pressure, renal function, and the NOS system in the kidney of SHR and normotensive Wistar-Kyoto rats (WKY).
METHODS

Animals and drug administration
Five-week-old male SHR/Izm and WKY/Izm rats were obtained from SLC (Shizuoka, Japan). The rats were housed in the animal care facility at Tohoku University School of Medicine, with free access to standard laboratory chow and tap water; rats were kept at a controlled temperature of 24 °C with 12-hour light/dark cycles. 11 Rats of each strain were randomly divided into either the control group (CON: n = 8 SHR; n = 6 WKY) or the PTV group (n = 8 SHR; n = 6 WKY). They were treated with either 0.5% carboxymethyl cellulose solution as the vehicle (CON) or vehicle-containing PTV (Kowa Pharmaceutical, Tokyo, Japan) at a dose of 2 mg/kg/day. This was selected as an antihypertensive dose after a pilot experiment (1 mg/kg/day and 2 mg/kg/day). PTV was administrated daily by gavage for 8 weeks. All protocols involving rats were reviewed and received prior approval by the Animal Welfare Committee at the Tohoku University School of Medicine.
Blood pressure measurement and preparation of plasma and urine samples Systolic blood pressure was measured every 2 weeks by tailcuff monitor (MK-2000, Muromachi Kikai, Tokyo, Japan). Rats were placed in narrow dark cabins for >15 minutes to ensure that they were calm; several premeasurements were performed prior to the formal measurement. Rats were placed in individual metabolic cages once every 2 weeks, and urine samples were collected on ice. On the final day of the protocol, rats were anesthetized with pentobarbital sodium (50 mg/kg, intraperitoneally) and blood samples were collected by decapitation. Samples were centrifuged for 10 minutes at 3,000 rpm, separated from sediment, and stored at −80 °C.
Measurement of biochemical parameters in plasma and urinary samples
Plasma creatinine, urea nitrogen, total cholesterol, triglycerides, free fatty acids, and glucose were measured by SRL Inc. (Tokyo, Japan). Urinary albumin and creatinine were measured by Oriental Yeast (Nagahama, Japan). NO x was measured by Griess reagent method with the nitrate/nitrite colorimetric assay kit (Cayman Chemical Company, Ann Arbor, MI). H 2 O 2 was measured by using the Amplex red hydrogen peroxide/peroxidase assay kit (Molecular Probes, Eugene, OR).
Preparation of tissue samples
The kidneys and thoracic aorta were removed, and kidneys were prepared for histological and immunoblotting assessment. Kidneys for histological assessment were fixed in 10% formalin, and kidneys for immunoblotting were sectioned into 3 sections: cortex (CO), outer medulla (OM), and inner medulla (IM). Sections were homogenized in phosphate-buffered saline containing 0.1 mmol/L phenylmethylsulfonyl fluoride. Samples were stored at −80 °C. Protein concentration was measured by using the Bradford method, with bovine γ globulin as the standard.
Histological assessment
Desmin immunohistochemical assessment was performed to evaluate the status of glomerular epithelial damage. Briefly, deparaffinized tissues were rehydrated in graded ethanol and rinsed in phosphate-buffered saline; they were then treated with 0.3% hydrogen peroxide in absolute ethanol for 5 minutes, followed by processing for immunostaining with antibodies against desmin (ab8470, Abcam, Cambridge, UK). The ratio of desmin-expressing area to whole glomeruli was presented as the mean ± SE of at least 30 glomeruli in every involved rat.
Masson's Trichrome staining was performed to measure the level of medullary interstitial fibrosis. For Masson's Trichrome staining, tissues were deparaffinized, rinsed in Wiegert's iron hematoxylin, and then stained by 3 different solutions (plasma stain solution A: acid fuchsine, xylidine ponceau, glacial acetic acid, and distilled water; solution B: phosphomolybdic acid; fibre stain solution C: light green SF yellowish). Images were measured by ImageJ (ver. 2.0.0, NIH, Bethesda, MD).
Western blotting
Western blotting was performed as described previously. 11 Primary antibodies were against eNOS, nNOS, iNOS, and phosphorylated-eNOS at Ser1177 and Thr495, (610297, 610309, 610432, 612392, 612706; BD Transduction Laboratories, San Jose, CA). Secondary IgG antibodies against mouse or rabbit were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Excess secondary antibody was removed by 3 to 4 washes in Tris-buffered saline with Tween-20, and immunoblots were developed by using an enhanced chemiluminescence kit (Super Signal; Thermo Fisher Scientific, Waltham, MA). Relative intensities of the bands-at 140 kDa for eNOS and phosphorylated-eNOS, at 155 kDa for nNOS, and at 130 kDa for iNOSwere quantified by using ImageJ. The intensities of the bands for each protein were normalized to those for á-tubulin as an internal standard; the intensity of the band in the CON group was assigned a value of 1. eNOS phosphorylation was defined as the ratio of phosphorylated-eNOS/eNOS, and the results of the CON group were assigned a value of 1.
Statistical analysis
Data are presented as mean ± SE. Differences between CON and PTV were evaluated by Student's t-test. Values of P <0.05 were considered to indicate statistical significance. Figure 1 shows the time courses of systolic blood pressure and urinary albumin excretion. PTV significantly decreased systolic blood pressure in SHR from week 6 to week 8 but did not change systolic blood pressure in WKY (Figure 1a) . PTV also significantly decreased urinary albumin excretion at week 8 in SHR but did not change urinary albumin excretion in WKY (Figure 1b) . Table 1 shows the effect of PTV on plasma parameters. PTV decreased plasma triglycerides and free fatty acids in SHR but only decreased triglycerides in WKY. PTV did not affect plasma creatinine, urea nitrogen, total cholesterol, or glucose in either strain. PTV did not increase urinary NO x excretion in SHR but significantly increased urinary NO x excretion in WKY. PTV tended to increase plasma NO x in both SHR (P < 0.06) and WKY (P < 0.07). PTV significantly decreased urinary H 2 O 2 excretion in SHR and plasma H 2 O 2 concentration in SHR and WKY.
RESULTS
Effect of PTV on blood pressure and urinary albumin excretion
Effect of PTV on plasma and urinary parameters
Effect of PTV on renal histology
Glomerular desmin expression was significantly increased in SHR, compared with WKY (Figure 2a,b) . PTV significantly decreased desmin expression in SHR but did not change the desmin expression in WKY. More renal interstitial fibrosis was observed in SHR, compared with WKY. PTV significantly attenuated the fibrosis (Figure 2c,d) . (c and d) , and eNOS (e and f) protein in the kidney and aorta of SHR and WKY. protein levels in the renal CO, OM, IM, and aorta were examined by western blotting and compared between the CON group (closed bars) and PTV group (open bars) (n = 8 SHR; n = 6 WKY). Each lane was loaded with a protein sample prepared from a different rat of both groups. Intensities of the bands for each protein were normalized to those for -tubulin, and the intensity of the band in the CON group was assigned a value of 1. (Figure 4 ) Effect of PTV on eNOS phosphorylation at S1177 (a and b) and T495 (c and d) in the kidney and aorta of SHR and WKY. The ratio of the relative intensities of the bands for the phosphorylated-eNOS to those of the total eNOS was calculated. The ratio in the CON group was assigned a value of 1. Data are the mean ± SE. ND; the bands were not detected. *P < 0.05, **P < 0.01 compared with the CON group. Abbreviations: CO, cortex; OM, outer medulla; IM, inner medulla; iNOS, inducible nitric oxide synthase; nNOS, neuronal nitric oxide synthase; eNOS, endothelial nitric oxide synthase; S1177, Serine1177; T495, Threonine495; PTV, pitavastatin; SHR, spontaneously hypertensive rats; WKY, Wistar-Kyoto rats.
Effect of PTV on NOS expression
In SHR, PTV significantly increased nNOS expression in the CO, OM, IM, and aorta by 149%, 415%, 294%, and 160%, respectively (Figure 3a) . PTV significantly increased iNOS expression in the IM by 235%; iNOS expression was not significantly changed in aorta and was not detected in CO or OM (Figure 3c ). PTV significantly increased eNOS expression in OM, IM, and aorta by 282%, 286%, and 189%, respectively, but did not affect eNOS expression in CO (Figure 3e) .
In WKY, PTV significantly increased nNOS expression in IM by 225% (Figure 3b ). PTV did not affect iNOS expression in IM or aorta (Figure 3d ). PTV significantly increased eNOS expression in CO and IM by 281% and 145%, respectively (Figure 3f ). PTV did not significantly change expression of NOS isoforms in aorta. Abbreviations: BUN, plasma urea nitrogen; CON, control groups; Cr, creatinine; FFA, free fatty acid; P-H 2 O 2 , plasma hydrogen peroxide concentration; P-NO x , plasma nitrite oxide concentration; PTV, pitavastatin-treated groups; SHR, spontaneously hypertensive rats; T-Cho, total cholesterol; TG, triglyceride; U-H 2 O 2 , urinary hydrogen peroxide excretion; U-NO x , urinary nitrite oxide excretion; WKY, Wistar-Kyoto rats. Data are mean ± SE; *P <0.05 vs. CON in respective strains; **P <0.01 vs. CON in respective strains.
Effect of PTV on eNOS phosphorylation
In SHR, PTV significantly enhanced eNOS phosphorylation at Ser1177 in IM by 198% but did not significantly affect phosphorylation in CO or OM (Figure 4a ). PTV significantly inhibited eNOS phosphorylation at Thr495 in OM and IM by 51% and 58%, respectively, but did not significantly affect phosphorylation in CO (Figure 4c) .
In WKY, PTV enhanced eNOS phosphorylation at Ser1177 in OM and IM by 406% and 258%, respectively (Figure 4b ). PTV did not affect eNOS phosphorylation at Thr495 in any (c and d) , and eNOS (e and f) protein in the kidney and aorta of SHR and WKY: the protein levels of nNOS in the renal CO, OM, IM, and aorta were examined by western blotting and compared between the CON group (closed bars) and PTV group (open bars) (n = 8 SHR; n = 6 WKY). Each lane was loaded with a protein sample prepared from a different rat of both groups. Intensities of the bands for each protein were normalized to those for á-tubulin, and the intensity of the band in the CON group was assigned a value of 1. Data are the mean ± SE. ND; the bands were not detected. **P <0.01 compared with the CON group. Abbreviations: CO, cortex; IM, inner medulla; iNOS, inducible nitric oxide synthase; nNOS, neuronal nitric oxide synthase; OM, outer medulla; PTV, pitavastatin; SHR, spontaneously hypertensive rats; WKY, Wistar-Kyoto rats.
portion of the kidney (Figure 4d ). PTV did not significantly affect phosphorylation status in aorta (Figure 4b,d) .
DISCUSSION
Clinical trials show potent renoprotective effects of PTV, although the precise mechanisms of the antihypertensive and renoprotective effects of PTV remain unclear. Several kinds of statins have been reported to have antihypertensive effects, related to changes in the NO system. SHR constitute a typical model of essential hypertension, in which ATV treatment has shown antihypertensive effects. 11 Thus, the present study examined the effects of PTV in SHR and WKY. PTV lowered blood pressure and albuminuria in SHR. PTV also attenuated glomerular desmin expression and medullary interstitial fibrosis in SHR. PTV tended to increase plasma NO x in both strains and significantly increased urinary NO x in WKY. PTV increased renal NOS expression and changed eNOS phosphorylation in both strains, represented as enhancement at Ser1177 and inhibition at Thr495. These results suggest that PTV-induced antihypertensive and renoprotective effects may be mediated through upregulation of the renal NO system, including increased NOS expression and altered eNOS phosphorylation.
We previously reported the effects of ATV in the kidney of SHR and WKY. 11 ATV upregulated NOS expression but inhibited eNOS phosphorylation at Ser1177 in the kidney of SHR. Moreover, ATV failed to change NOS expression in the kidney of WKY. 11 In contrast to ATV, the present study showed that PTV increased eNOS expression and altered eNOS phosphorylation in the kidney of both SHR and WKY, represented as enhancement at Ser1177 and inhibition at Thr495. These contrasting findings suggest that the effects of ATV and PTV on the NO system differ in terms of eNOS phosphorylation. 11 Previous studies have reported eNOS expression in the kidney and vasculature of SHR to be higher than eNOS expression in WKY 23, 24 ; moreover, this expression is reduced by hydralazine, resulting in the downregulation of urinary NO x excretion, 11 which indicates that blood pressure serves as a regulator of eNOS expression and NO production. 17 Thus, the present study showed that PTV increased urinary NO x excretion in WKY but not in SHR, which might be related to the antihypertension-induced NO x downregulation. Thus, we performed a similar treatment by using PTV in WKY as a normotensive control to exclude the influence of blood pressure. PTV did not affect blood pressure but significantly increased urinary NO x in WKY, suggesting that PTV could upregulate the NO system, independent of blood pressure.
PTV enhanced eNOS phosphorylation at Ser1177 in IM and inhibited eNOS phosphorylation at Thr495 in OM and IM of SHR; similar changes were observed in WKY. These results suggest that PTV upregulates both eNOS expression and eNOS availability in the kidney since eNOS expression and phosphorylation at Ser1177 are critical factors in the regulation of its enzymatic activity. 25 PTV activated eNOS phosphorylation at Ser1177 in human endothelial cells. 22 In contrast, eNOS phosphorylation at Thr495 has been reported to inhibit NO production and increase oxidative stress in mouse aortic endothelial cells. 26 Thus, the present study is the first to report that PTV can activate eNOS phosphorylation at Ser1177 and inhibit eNOS phosphorylation at Thr495 in vivo. The ratio of the relative intensities of the bands for the phosphorylated-eNOS to those of the total eNOS was calculated. The ratio in the CON group was assigned a value of 1. Data are the mean ± SE. *P < 0.05, **P < 0.01 compared with the CON group. Abbreviations: CO, cortex; eNOS, endothelial nitric oxide synthase; IM, inner medulla; OM, outer medulla; PTV, pitavastatin; S1177, Serine1177; SHR, spontaneously hypertensive rats; T495, Threonine495; WKY, Wistar-Kyoto rats.
We previously reported that ATV inhibited eNOS phosphorylation at Ser1177 in the kidney of SHR, although the depressor effect of ATV was similar to that of PTV. 11 These results suggest that the mechanisms by which PTV and ATV affect the NO system might differ. In this regard, both PTV and ATV increased eNOS expression in circulating endothelial progenitor cells, whereas only PTV stimulated eNOS phosphorylation at Ser1177. 21 Clinical trials have reported differences in the renoprotective effects of PTV and ATV in chronic kidney disease patients. PTV elevated estimated glomerular filtration rate, 8 whereas ATV attenuated the reduction of creatinine clearance 6 but failed to reverse the reduction of estimated glomerular filtration rate. 7 Differences in the renoprotective effects of PTV and ATV may be partly explained by differences in the effects of these drugs on eNOS phosphorylation in the kidney.
Several studies have reported on the antihypertensive effect of statins, which may be caused by NO-dependent vasodilation and inhibition of renal tubular Na + transport. Lovastatin increases renal medullary blood flow and renal interstitial pressure and resets the pressure-natriuresis relationship to a lower level; upon lovastatin treatment, renal interlobular arteries are less responsive to vasoconstrictor stimuli in SHR. 9, 27 This suggests that the antihypertensive effects of statins in SHR are, in part, related to vasodilation in the glomerular and medullary circulation. In addition to the vascular effects of statins, pravastatin has been reported to increase NO production in the thick ascending limb of Henle's loop. 28 In simvastatin-treated Wistar rats, acetylcholine-induced vasodilation was enhanced in the afferent arterioles; notably, Nω-nitro-l-arginine methyl ester (l-NAME), an inhibitor of NOS, completely blocked the response to acetylcholine. 29 The present study failed to provide precise molecular mechanisms for PTV-induced NOS activity in the kidney. Although numerous studies have reported the effects of statins on eNOS expression and phosphorylation in vessels and cultured endothelial cells, the precise molecular mechanisms of statin-induced NOS activity remain unclear. In addition, molecular mechanisms of statin-induced NOS activity in renal tubules have not been reported; these tubules include the proximal tubules, thick ascending limb, and collecting ducts, respectively. Importantly, the divergent response to PTV might be due to different tubular cell types. Furthermore, PTV concentration in CO, OM, and IM might differ according to renal concentration ability.
Oxidative stress regulates eNOS activity through expression, dimer uncoupling, inhibitory phosphorylation, and peroxynitrite generation. [30] [31] [32] Divergent regulation of NOS activity between PTV and ATV may be caused by differences in the regulation of oxidative stress. ATV was reported to increase oxidative stress in several organs and cause prediabetes dysfunction. 33, 34 PTV was reported to cause more potent oxidative stress reduction than rosuvastatin. 35 The present study showed that PTV significantly reduced urinary H 2 O 2 excretion in SHR and plasma H 2 O 2 concentration in SHR and WKY. Furthernore, PTV significantly decreased renal NADPH oxidase activity, while ATV failed to do so (data not shown). The divergent regulation of oxidative stress between ATV and PTV might contribute to differences in eNOS activation.
Several studies have indicated that the renoprotective effects of statins are independent of antihypertension or the NO system. In L-NAME-induced hypertensive rats, ATV ameliorated albuminuria and decreased GFR, while simvastatin ameliorated renal damage, renal interstitial fibrosis, inflammation, and cell proliferation without a depressor effect. 36, 37 Renoprotective effects might be related to the pleiotropic effects of statins, such as antifibrosis 38 and antioxidant. 39 Further studies are required to elucidate precise molecular mechanisms for the renoprotective effects of PTV.
In summary, PTV increased NOS expression and altered eNOS phosphorylation in the kidney of both SHR and WKY, represented as enhancement at Ser1177 and inhibition at Thr495. These results differ from those reported in a previous study of ATV. 38 We conclude that the antihypertensive and renoprotective effects of PTV may be mediated in part by upregulation of the NO system in the kidney.
